China Healthwise Holdings Valuation
Is 348 undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
3/6Valuation Score 3/6
Below Fair Value
Significantly Below Fair Value
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of 348 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: 348 (HK$0.08) is trading below our estimate of fair value (HK$0.78)
Significantly Below Fair Value: 348 is trading below fair value by more than 20%.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for 348?
Key metric: As 348 is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.
| What is 348's PS Ratio? | |
|---|---|
| PS Ratio | 0.5x |
| Sales | HK$126.42m |
| Market Cap | HK$60.87m |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | 1x |
| Enterprise Value/EBITDA | -1x |
| PEG Ratio | n/a |
Price to Sales Ratio vs Peers
How does 348's PS Ratio compare to its peers?
| Company | Forward PS | Estimated Growth | Market Cap |
|---|---|---|---|
| Peer Average | 0.4x | ||
1348 Quali-Smart Holdings | 0.5x | n/a | HK$81.1m |
209 Winshine Science | 0.07x | n/a | HK$33.4m |
1792 CMON | 0.2x | n/a | HK$47.7m |
765 Perfectech International Holdings | 1.1x | n/a | HK$163.5m |
348 China Healthwise Holdings | 0.5x | n/a | HK$60.9m |
Price-To-Sales vs Peers: 348 is expensive based on its Price-To-Sales Ratio (0.5x) compared to the peer average (0.4x).
Price to Sales Ratio vs Industry
How does 348's PS Ratio compare vs other companies in the HK Leisure Industry?
Price-To-Sales vs Industry: 348 is good value based on its Price-To-Sales Ratio (0.5x) compared to the Hong Kong Leisure industry average (0.6x).
Price to Sales Ratio vs Fair Ratio
What is 348's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current PS Ratio | 0.5x |
| Fair PS Ratio | n/a |
Price-To-Sales vs Fair Ratio: Insufficient data to calculate 348's Price-To-Sales Fair Ratio for valuation analysis.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analyst Forecast: Insufficient data to show price forecast.